Latest Breaking News On - Joshua bartch - Page 18 : comparemela.com

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC (MYCOF) - Mydecine Exports Psilocybin Mushrooms From Jamaica To Canada — An Industry First

Psychedelics and biopharma company Mydecine (CSE:MYCO) (OTC:MYCOF) recently announced the successful export of 20 kilograms of dried psilocybin mushrooms from a cultivation facility in Jamaica to a facility in Canada. A World’s First: According to the Denver-based company, this represents the first-ever legal international export of psilocybin mushrooms. Mydecine was able to receive the shipment by the exercise of a Health Canada Schedule 1 Dealer’s License held by its Canadian facility, which permits the “import/export, research and development, cultivation, product development, and commercial sale of active psychedelic medicinal compounds.” “We are now able to access a quality source of much needed product for both our own research purposes, as well as provide CGMP naturally-derived psilocybin to sell and transfer to other licensed research facilities around the globe,” Mydecine CEO and Chairman Joshua Bartch said in a prepared statement.

Damon michaelsJoshua bartchChairman joshua bartchCo founder damon michaelsடாமன் மைக்கேல்ஸ்இணை நிறுவனர் டாமன் மைக்கேல்ஸ்

Breaking News: Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain | Breaking News: Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply ChainFinancial Buzz

Breaking News: Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain | Breaking News: Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply ChainFinancial Buzz
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

Damon michaelsJoshua bartchMydecine innovations groupMydecine coHealth canada scheduleCanadian current good manufacturing practiceChief operatingடாமன் மைக்கேல்ஸ்ஆரோக்கியம் கனடா அட்டவணைகனடியன் தற்போதைய நல்ல உற்பத்தி ப்ர்யாக்டீஸ்தலைமை இயங்குகிறது

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Pipeline NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DENVER, Feb. 24, 2021 (GLOBE NEWSWIRE) Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced an exclusive partnership with Applied Pharmaceutical Innovation (API) at the University of Alberta, as well as expanded capabilities that enables support of multiple drug development and clinical trial programs simultaneously. “With our expanded relationship with API, we can now synthesise multiple molecules concurrently as well as run research and development and pre-clinicals on site,” said Rob Roscow, Chief Scientific Officer and Co-founder of Mydecine. “We now have the ability to accelerate both natural product research and novel drug design, specific

United statesAndrew macisaacCharles leeJoshua bartchAnne donohoe nick opichMydecine innovations group incUniversity of albertaMydecine innovations group media contactsStrategic communicationsMydecine innovations groupCanadian securities exchangeHealth canadaCorp communicationsPartnership supports mydecineDrug developmentClinical trials

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap s Mental Health Technology

Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate … Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office (USPTO) and the Canadian Intellectual Property Office.

United statesJack bunceJosh bartchCharles leeJoshua bartchAnne donohoe nick opichMindleap healthCorp communicationOur servicesMydecine innovations group media contactsMindleap health platform services disclaimerMindleap health incTrademark officeDigital mental healthCanadian securities exchangeCanadian intellectual property office

MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC (MMEDF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC (MYCOF) - Psyched: MindMed Enters Psychedelics 2 0, Mind Cure Raises $18M, Mydecine Raises $13M

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit. The proceeds will be used to finance product research and development, advance the company’s technological capabilities, marketing expenditures and product awareness, as well as for working capital. So far, Mind Cure has raised almost CA$31 million ($24.4 million) to date. The company’s operations are divided between five spheres, which include: A line of non-psychedelic supplements using functional mushroom formulations that are already available to consumers.

Joshua bartchMiri halperin wernliFelix lustenbergerTrademark officeMydecine innovations groupHead of clinical developmentPharmadrug incCure health incMind cure closesCure healthMind cureMed dives into psychedelicsMindshift compoundsMindmed presidentClinical developmentMiri halperin